Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Links shared publicly online about this topic.

941
total visits

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

View full resource at news-medical.net

Tags: Sexual Health, Drug, Phase 1 Clinical Trial, Clinical Trial, Men's Health, Sex and Intimacy, Sexual Dysfunction